DLL3 Is Expressed in GEP-Neuroendocrine Neoplasms with Loss of RB1 and Has Prognostic Significance
Introduction: The negative notch regulator DLL3 has gained increasing attention in tumors with neuroendocrine features, in particular SCLC, LCNEC and neuroendocrine prostate cancer, both as prognostic marker and candidate therapeutic target. No data are available on the expression of DLL3 in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs).
Aim(s): The aim of the present study is to evaluate DLL3 expression in different GEP-NENs tissues and assess the correlation with disease stage, clinical features and RB1 loss.
Materials and methods: DLL3 and RB1 expression was retrospectively evaluated on FPPE samples from 43 patients with GEP-NENs. The immunostaining was scored positive if ≥1% of the tumor cells showed cytoplasmic/membranous (DLL3) or nuclear (RB1) localization.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Liverani C
To read the full abstract, please log into your ENETS Member account.